Cargando…

Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels

The potential therapeutic effects of probiotic bacteria in rheumatoid arthritis (RA) remain controversial. Thus, this study aimed to discover potential therapeutic bacteria based on the relationship between the gut microbiome and rheumatoid factor (RF) in RA. Bacterial genomic DNA was extracted from...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Yunju, Jhun, JooYeon, Lee, Seon-Yeong, Na, Hyun Sik, Choi, JeongWon, Cho, Keun-Hyung, Lee, Seung Yoon, Lee, A Ram, Park, Sang-Jun, You, Hyun Ju, Kim, Ji-Won, Park, Myeong Soo, Kwon, Bin, Cho, Mi-La, Ji, Geun Eog, Park, Sung-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634832/
https://www.ncbi.nlm.nih.gov/pubmed/34867956
http://dx.doi.org/10.3389/fimmu.2021.736196
_version_ 1784608193010204672
author Jeong, Yunju
Jhun, JooYeon
Lee, Seon-Yeong
Na, Hyun Sik
Choi, JeongWon
Cho, Keun-Hyung
Lee, Seung Yoon
Lee, A Ram
Park, Sang-Jun
You, Hyun Ju
Kim, Ji-Won
Park, Myeong Soo
Kwon, Bin
Cho, Mi-La
Ji, Geun Eog
Park, Sung-Hwan
author_facet Jeong, Yunju
Jhun, JooYeon
Lee, Seon-Yeong
Na, Hyun Sik
Choi, JeongWon
Cho, Keun-Hyung
Lee, Seung Yoon
Lee, A Ram
Park, Sang-Jun
You, Hyun Ju
Kim, Ji-Won
Park, Myeong Soo
Kwon, Bin
Cho, Mi-La
Ji, Geun Eog
Park, Sung-Hwan
author_sort Jeong, Yunju
collection PubMed
description The potential therapeutic effects of probiotic bacteria in rheumatoid arthritis (RA) remain controversial. Thus, this study aimed to discover potential therapeutic bacteria based on the relationship between the gut microbiome and rheumatoid factor (RF) in RA. Bacterial genomic DNA was extracted from the fecal samples of 93 RA patients and 16 healthy subjects. Microbiota profiling was conducted through 16S rRNA sequencing and bioinformatics analyses. The effects of Bifidobacterium strains on human peripheral blood mononuclear cells and collagen-induced arthritis (CIA) mice were assessed. Significant differences in gut microbiota composition were observed in patients with different RF levels. The relative abundance of Bifidobacterium and Collinsella was lower in RF-high than in RF-low and RF-negative RA patients, while the relative abundance of Clostridium of Ruminococcaceae family was higher in RF-high than in RF-low and RF-negative patients. Among 10 differentially abundant Bifidobacterium, B. longum RAPO exhibited the strongest ability to inhibit IL-17 secretion. Oral administration of B. longum RAPO in CIA mice, obese CIA, and humanized avatar model significantly reduced RA incidence, arthritis score, inflammation, bone damage, cartilage damage, Th17 cells, and inflammatory cytokine secretion. Additionally, B. longum RAPO significantly inhibited Th17 cells and Th17-related genes—IL-17A, IRF4, RORC, IL-21, and IL-23R—in the PBMCs of rheumatoid arthritis patients. Our findings suggest that B. longum RAPO may alleviate RA by inhibiting the production of IL-17 and other proinflammatory mediators. The safety and efficacy of B. longum RAPO in patients with RA and other autoimmune disorders merit further investigation.
format Online
Article
Text
id pubmed-8634832
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86348322021-12-02 Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels Jeong, Yunju Jhun, JooYeon Lee, Seon-Yeong Na, Hyun Sik Choi, JeongWon Cho, Keun-Hyung Lee, Seung Yoon Lee, A Ram Park, Sang-Jun You, Hyun Ju Kim, Ji-Won Park, Myeong Soo Kwon, Bin Cho, Mi-La Ji, Geun Eog Park, Sung-Hwan Front Immunol Immunology The potential therapeutic effects of probiotic bacteria in rheumatoid arthritis (RA) remain controversial. Thus, this study aimed to discover potential therapeutic bacteria based on the relationship between the gut microbiome and rheumatoid factor (RF) in RA. Bacterial genomic DNA was extracted from the fecal samples of 93 RA patients and 16 healthy subjects. Microbiota profiling was conducted through 16S rRNA sequencing and bioinformatics analyses. The effects of Bifidobacterium strains on human peripheral blood mononuclear cells and collagen-induced arthritis (CIA) mice were assessed. Significant differences in gut microbiota composition were observed in patients with different RF levels. The relative abundance of Bifidobacterium and Collinsella was lower in RF-high than in RF-low and RF-negative RA patients, while the relative abundance of Clostridium of Ruminococcaceae family was higher in RF-high than in RF-low and RF-negative patients. Among 10 differentially abundant Bifidobacterium, B. longum RAPO exhibited the strongest ability to inhibit IL-17 secretion. Oral administration of B. longum RAPO in CIA mice, obese CIA, and humanized avatar model significantly reduced RA incidence, arthritis score, inflammation, bone damage, cartilage damage, Th17 cells, and inflammatory cytokine secretion. Additionally, B. longum RAPO significantly inhibited Th17 cells and Th17-related genes—IL-17A, IRF4, RORC, IL-21, and IL-23R—in the PBMCs of rheumatoid arthritis patients. Our findings suggest that B. longum RAPO may alleviate RA by inhibiting the production of IL-17 and other proinflammatory mediators. The safety and efficacy of B. longum RAPO in patients with RA and other autoimmune disorders merit further investigation. Frontiers Media S.A. 2021-11-15 /pmc/articles/PMC8634832/ /pubmed/34867956 http://dx.doi.org/10.3389/fimmu.2021.736196 Text en Copyright © 2021 Jeong, Jhun, Lee, Na, Choi, Cho, Lee, Lee, Park, You, Kim, Park, Kwon, Cho, Ji and Park https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jeong, Yunju
Jhun, JooYeon
Lee, Seon-Yeong
Na, Hyun Sik
Choi, JeongWon
Cho, Keun-Hyung
Lee, Seung Yoon
Lee, A Ram
Park, Sang-Jun
You, Hyun Ju
Kim, Ji-Won
Park, Myeong Soo
Kwon, Bin
Cho, Mi-La
Ji, Geun Eog
Park, Sung-Hwan
Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels
title Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels
title_full Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels
title_fullStr Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels
title_full_unstemmed Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels
title_short Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels
title_sort therapeutic potential of a novel bifidobacterium identified through microbiome profiling of ra patients with different rf levels
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634832/
https://www.ncbi.nlm.nih.gov/pubmed/34867956
http://dx.doi.org/10.3389/fimmu.2021.736196
work_keys_str_mv AT jeongyunju therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT jhunjooyeon therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT leeseonyeong therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT nahyunsik therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT choijeongwon therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT chokeunhyung therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT leeseungyoon therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT leearam therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT parksangjun therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT youhyunju therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT kimjiwon therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT parkmyeongsoo therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT kwonbin therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT chomila therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT jigeuneog therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels
AT parksunghwan therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels